Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Shattuck Labs, Inc. is a biotechnology company focused on developing innovative treatments for inflammatory and immune-mediated diseases. Its lead program, SL-325, is a high-affinity monoclonal antibody targeting the DR3 receptor to inhibit the TL1A pathway, aiming to treat conditions like IBD. The company leverages protein engineering, advances biologics into clinical trials, and collaborates with biopharma partners to create first-in-class immunotherapies.
This description was generated via AI from an annual report. Updated about 1 year ago.